Mobocertinib

DRUG4 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Healthy VolunteersHepatic ImpairmentNon-Small Cell Lung CancerRenal Impairment

Phase 1

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Active, not recruitingNCT03807778

TakedaNon-Small Cell Lung Cancer

Start: 2019-02-04End: 2026-09-30Updated: 2026-05-14

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

CompletedNCT03811834

Millennium Pharmaceuticals, Inc.Healthy Volunteers

Start: 2019-01-22End: 2019-03-11Updated: 2024-02-12

A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys

CompletedNCT04056455

Millennium Pharmaceuticals, Inc.Healthy Volunteers, Renal Impairment

Start: 2020-03-04End: 2022-04-20Updated: 2024-01-08

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

CompletedNCT04056468

Millennium Pharmaceuticals, Inc.Healthy Volunteers, Hepatic Impairment

Start: 2020-10-09End: 2022-02-26Updated: 2023-11-03

Related Papers

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.

2024-05-245 citations

Mobocertinib: Mechanism of action, clinical, and translational science

Clinical and Translational Science2024-03-0116 citations

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion–positive non–small cell lung cancer

Expert Review of Anticancer Therapy2022-12-209 citations